Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial

Published on Jun 1, 2016in Lancet Oncology33.752
· DOI :10.1016/S1470-2045(16)00111-X
Christian Carrie49
Estimated H-index: 49
Ali Hasbini10
Estimated H-index: 10
+ 19 AuthorsSophie Dussart9
Estimated H-index: 9
Summary Background How best to treat rising prostate-specific antigen (PSA) concentration after radical prostatectomy is an urgent clinical question. Salvage radiotherapy delays the need for more aggressive treatment such as long-term androgen suppression, but fewer than half of patients benefit from it. We aimed to establish the effect of adding short-term androgen suppression at the time of salvage radiotherapy on biochemical outcome and overall survival in men with rising PSA following radical prostatectomy. Methods This open-label, multicentre, phase 3, randomised controlled trial, was done in 43 French study centres. We enrolled men (aged ≥18 years) who had received previous treatment for a histologically confirmed adenocarcinoma of the prostate (but no previous androgen deprivation therapy or pelvic radiotherapy), and who had stage pT2, pT3, or pT4a (bladder neck involvement only) in patients who had rising PSA of 0·2 to less than 2·0 μg/L following radical prostatectomy, without evidence of clinical disease. Patients were randomly assigned (1:1) centrally via an interactive web response system to standard salvage radiotherapy (three-dimensional [3D] conformal radiotherapy or intensity modulated radiotherapy, of 66 Gy in 33 fractions 5 days a week for 7 weeks) or radiotherapy plus short-term androgen suppression using 10·8 mg goserelin by subcutaneous injection on the first day of irradiation and 3 months later. Randomisation was stratified using a permuted block method according to investigational site, radiotherapy modality, and prognosis. The primary endpoint was progression-free survival, analysed in the intention-to-treat population. This trial is registered with, number NCT00423475. Findings Between Oct 19, 2006, and March 30, 2010, 743 patients were randomly assigned, 374 to radiotherapy alone and 369 to radiotherapy plus goserelin. Patients assigned to radiotherapy plus goserelin were significantly more likely than patients in the radiotherapy alone group to be free of biochemical progression or clinical progression at 5 years (80% [95% CI 75–84] vs 62% [57–67]; hazard ratio [HR] 0·50, 95% CI 0·38–0·66; p vs none of 372 patients in the radiotherapy alone group). Three (8%) of 366 patients had grade 3 or worse hot flushes and one patient had grade 3 or worse sweating in the radiotherapy plus goserelin group versus none of 372 patients in the radiotherapy alone group. The most common late adverse events of grade 3 or worse were genitourinary events (29 [8%] in the radiotherapy alone group vs 26 [7%] in the radiotherapy plus goserelin group) and sexual disorders (20 [5%] vs 30 [8%]). No treatment-related deaths occurred. Interpretation Adding short-term androgen suppression to salvage radiotherapy benefits men who have had radical prostatectomy and whose PSA rises after a postsurgical period when it is undetectable. Radiotherapy combined with short-term androgen suppression could be considered as a reasonable option in this population. Funding French Ministry of Health, AstraZeneca, and La Ligue Contre le Cancer.
📖 Papers frequently viewed together
201260.39The Lancet
19 Authors (Michel Bolla, ..., Laurence Collette)
605 Citations
728 Citations
322 Citations
#1William U. Shipley (Harvard University)H-Index: 100
#2W. SeiferheldH-Index: 18
Last. H.M. Sandler (Cedars-Sinai Medical Center)H-Index: 14
view all 20 authors...
Hospitalization final 90 days of life 48.3% 64.0% .0004 Hospitalization final 30 days of life 31.5% 61.5% <.0001 Died in a hospital 8.4% 38.5% <.0001 Hospice care provided 69.6% 47.0% <.0001 Hospice median stay (days) 22 days 13 days .0004 Mean inpatient costs final 90 days of life 12,976 0,398 .0065 Mean total costs final 90 days of life 20,771 8,088 .0128 Volume 94 Number 1 2016 Selected for Clinical Trials and Plenary Sessions 3
20 CitationsSource
#1D. BartkowiakH-Index: 1
#2A. J. SchraderH-Index: 1
Last. T. WiegelH-Index: 1
view all 3 authors...
Hintergrund: Nach radikaler Prostatektomie (RP) sind praoperativer PSA-Wert, Gleason-Score, pT-Stadium, der Status der Samenblasen und der Resektionsrander wesentliche Risiko-Indikatoren fur ein biochemisches oder klinisches Rezidiv. Binnen 5 Jahren kommt es je nach Tumorstadium bei 50–70% der Hochrisikopatienten zum biochemischen Progress. Behandlungsoptionen unter diesen Bedingungen sind die adjuvante Strahlentherapie (ART, bei nicht detektierbarem PSA) oder die Salvage-Radiotherapie (SRT, bei...
1 CitationsSource
#1Stephen J. Freedland (Duke University)H-Index: 96
#2R. Bryan Rumble (American Society of Clinical Oncology)H-Index: 25
Last. Howard M. Sandler (Cedars-Sinai Medical Center)H-Index: 96
view all 9 authors...
Purpose To endorse the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on adjuvant and salvage radiotherapy after prostatectomy. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines developed by other professional organizations.
65 CitationsSource
#1Alberto BrigantiH-Index: 96
#2Thomas WiegelH-Index: 50
Last. Hein Van Poppel (Katholieke Universiteit Leuven)H-Index: 26
view all 14 authors...
Background: Previous randomised trials demonstrated that adjuvant radiation therapy (aRT) improves cancer control in patients with pT3 prostate cancer (PCa). However, there is currently no evidence supporting early salvage radiation therapy (eSRT) as equivalent to aRT in improving freedom from biochemical recurrence (BCR) after radical prostatectomy (RP). Objective: To evaluate BCR-free survival for aRT versus observation followed by eSRT in cases of relapse in patients undergoing RP for pT3pN0,...
142 CitationsSource
#1Joanne W. Jang (UPenn: University of Pennsylvania)H-Index: 8
#2Wei-Ting Hwang (UPenn: University of Pennsylvania)H-Index: 62
Last. Neha Vapiwala (UPenn: University of Pennsylvania)H-Index: 26
view all 7 authors...
Purpose The addition of androgen deprivation therapy (ADT) to definitive external beam radiation therapy (RT) improves outcomes in higher-risk prostate cancer patients. However, the benefit of ADT with salvage RT in post-prostatectomy patients is not clearly established. Our study compares biochemical outcomes in post-prostatectomy patients who received salvage RT with or without concurrent ADT. Methods and Materials Of nearly 2,000 post-prostatectomy patients, we reviewed the medical records of...
15 CitationsSource
#1Alessandra Siegmann (Charité)H-Index: 12
#2Dirk BottkeH-Index: 14
Last. Thomas WiegelH-Index: 50
view all 9 authors...
Abstract Purpose Salvage radiotherapy (SRT) is applied routinely in patients with biochemical relapse after radical prostatectomy (RP). However, only ∼30% of these patients achieve a durable response after 10years. As a standard, 66Gy are given, ideally with a PSA below 0.5ng/ml. We tried to determine more precisely the optimal PSA for starting SRT. Material and methods In 301 prostate cancer patients without hormonal treatment, we analysed the impact on the biochemical response (bNED) to SRT of...
47 CitationsSource
#1Hans Geinitz (LMU: Ludwig Maximilian University of Munich)H-Index: 30
#2Martina G. Riegel (LMU: Ludwig Maximilian University of Munich)H-Index: 1
Last. Carsten Nieder (University of Tromsø)H-Index: 30
view all 8 authors...
Purpose This study attempts to improve our understanding of the role of salvage radiotherapy (SRT) in patients with prostate-specific antigen (PSA) relapse after radical prostatectomy with regard to biochemical control, rate of distant metastasis, and survival. Methods and Materials We performed a retrospective analysis of 96 men treated with conformal prostate bed SRT (median, 64.8 Gy) at a single institution (median follow-up, 70 months). The majority had intermediate- or high-risk prostate ca...
30 CitationsSource
#1Emmanuel S. Antonarakis (Johns Hopkins University)H-Index: 63
#2Zhaoyong Feng (Johns Hopkins University)H-Index: 25
Last. Mario A. Eisenberger (Johns Hopkins University)H-Index: 93
view all 8 authors...
Study Type – Prognosis (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Patients with biochemical recurrence after prostatectomy often develop subsequent metastases. However, the natural history of metastatic progression in men who have not received subsequent therapies before developing metastases has been understudied. Here, we describe the largest known cohort of men with PSA-recurrent prostate cancer after prostatectomy who have not received additional ...
190 CitationsSource
A progressively rising level of serum prostate specific antigen (PSA) after radical prostatectomy (RP) invariably indicates the recurrence of prostate cancer. The optimal management of patients with post-RP PSA relapse has remained uncertain due to a wide variability in the natural course of post-RP PSA relapse and the inability to separate a recurrent disease confined to the prostate bed from that with occult distant metastasis. Management uncertainty is further compounded by the lack of phase ...
22 CitationsSource
#1Stephen A. Boorjian (Fox Chase Cancer Center)H-Index: 80
#2R. Jeffrey Karnes (Mayo Clinic)H-Index: 70
Last. Michael L. Blute (Mayo Clinic)H-Index: 128
view all 6 authors...
Purpose: Although secondary radiation therapy decreases the risk of biochemical progression after radical prostatectomy, its impact on metastasis and survival is less well established. We evaluated the impact of adjuvant and salvage radiotherapy on clinical progression and mortality.Materials and Methods: A total of 361 patients who received adjuvant radiation were matched based on clinicopathological features to patients who did not receive adjuvant radiation in a 2:1 case-control ratio. Postop...
68 CitationsSource
Cited By232
#1Frank Paulsen (University of Tübingen)H-Index: 30
#2Jens Bedke (University of Tübingen)H-Index: 31
Last. Arndt-Christian Müller (University of Tübingen)H-Index: 18
view all 9 authors...
The extent of lymphadenectomy and clinical features influence the risk of occult nodes in node-negative prostate cancer. We derived a simple estimation model for the negative predictive value (npv) of histopathologically node-negative prostate cancer patients (pN0) to guide adjuvant treatment. Approximations of sensitivities in detecting lymph node metastasis from current publications depending on the number of removed lymph nodes were used for a theoretical deduction of a simplified formulation...
#1Peter E. Lonergan (UCSF: University of California, San Francisco)H-Index: 12
#2Janet E. Cowan (UCSF: University of California, San Francisco)H-Index: 43
Last. Peter R. Carroll (UCSF: University of California, San Francisco)H-Index: 141
view all 6 authors...
Background null A detectable prostate-specific antigen (PSA) following radical prostatectomy (RP) is an unfavorable prognostic factor. However, not all men with a detectable PSA experience recurrence. We describe the natural history and outcomes in men with a detectable PSA following RP in a contemporary cohort. null Methods null A retrospective analysis of men who underwent RP for non-metastatic prostate cancer at the University of California, San Francisco from 2000 to 2020 was performed. A de...
#1Pirus Ghadjar (University of Bern)H-Index: 29
#2Stefanie HayozH-Index: 12
Last. Ludwig Plasswilm (University of Bern)H-Index: 15
view all 72 authors...
Abstract null null Background null Salvage radiotherapy (SRT) is utilized for biochemical progression of prostate cancer after radical prostatectomy (RP). null null null Objective null To report the outcomes of the SAKK 09/10 trial comparing conventional and dose-intensified SRT. null null null Design, setting, and participants null SAKK 09/10 was a randomized, multicenter, phase 3 trial that recruited men with biochemical progression after RP. null null null Intervention null Patients were rand...
3 CitationsSource
#2Loig VaugierH-Index: 10
Last. Stéphane SupiotH-Index: 29
view all 9 authors...
Prostate cancer recurrence in patients previously treated with radical prostatectomy and radiation therapy is challenging. Re-irradiation could be an option, but data regarding efficacy and safety are lacking. We retrospectively evaluated salvage re-irradiation for local recurrence after prostatectomy and external beam radiation therapy. We collected data from 48 patients who underwent salvage reirradiation with stereotactic radiation therapy for local prostate cancer recurrence in the prostatic...
#1Sophia C. Kamran (Harvard University)H-Index: 16
#2Anthony L. Zietman (Harvard University)H-Index: 80
OBJECTIVES To present an overview of radiation therapy (RT) for prostate cancer over the past decade. METHODS The literature on prostate cancer radiation therapy was reviewed and summarised. Radiation therapy (RT) for prostate cancer has dramatically evolved in the past decade, with superior techniques and exciting advances, pushing the role of the radiation oncologist to new frontiers. RESULTS Innovations in imaging, treatment delivery, and a deeper understanding of biology has resulted in more...
#1Nicholas G. Zaorsky (Penn State Cancer Institute)H-Index: 28
#2Jeremie Calais (UCLA: University of California, Los Angeles)H-Index: 20
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
view all 7 authors...
More than 40% of men with intermediate-risk or high-risk prostate cancer will experience a biochemical recurrence after radical prostatectomy. Clinical guidelines for the management of these patients largely focus on the use of salvage radiotherapy with or without systemic therapy. However, not all patients with biochemical recurrence will go on to develop metastases or die from their disease. The optimal pre-salvage therapy investigational workup for patients who experience biochemical recurren...
The current standard for the management of locally advanced and early-stage metastatic prostate cancer relies on a backbone of androgen deprivation therapy (ADT) combined with radiotherapy (RT), a regimen that at a glance appears relatively straightforward. The emergence of newer diagnostic, genomic and imaging modalities have allowed for better disease risk-stratification and opened avenues for the development of more patient-centered treatment strategies. This review aims to highlight the cent...
1 CitationsSource
#1Marco M. E. Vogel (TUM: Technische Universität München)H-Index: 9
#2Sabrina Dewes (TUM: Technische Universität München)H-Index: 4
Last. Kilian Schiller (TUM: Technische Universität München)H-Index: 10
view all 9 authors...
Introduction: Prostate-specific membrane antigen-positron emission tomography-(PSMA-PET) imaging facilitates dose-escalated salvage radiotherapy (DE-SRT) with simultaneous-integrated boost (SIB) for PET-positive lesions in patients with prostate cancer (PC). Therefore, we aimed to compare toxicity rates of DE-SRT with SIB to conventional SRT (C-SRT) without SIB and to report outcome. Material and Methods: We evaluated 199 patients who were treated with SRT between 06/2014-06/2020. 101 patients r...
OBJECTIVES Prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) is a novel imaging tool with an evolving role in the management of prostate cancer. This study aims to retrospectively evaluate the impact of 68Ga-PSMA PET/CT on prostate cancer staging and definitive radiation therapy planning. METHODS Between April 2015 and June 2020, 366 men with prostate cancer were evaluated with 68Ga-PSMA PET/CT. Of these, 108 patients had PSMA PET/CT before radiation therapy. Radiation was g...
#1Srinivas Chilukuri (Apollo Hospitals)H-Index: 2
#2Vedang MurthyH-Index: 26
Three contemporary randomised controlled trials (RCTs) namely RAVES, RADICALS, and GETUGAFU 17 were published recently addressing the long-standing debate on "adjuvant (aRT) versus salvage radiation therapy (SRT)" in patients undergoing radical prostatectomy (RP). Although the three recent trials which differ in their design are not mature enough to report endpoints of metastases free survival (MFS) or overall survival, they have unequivocally shown that early SRT was either similar or non-infer...